X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Celebrating the success of the COVID-19 vaccines, and looking to the future

By Michael Ybarra  |    March 27, 2023
It’s been over three years since I saw my first COVID-19 patient in the emergency department. The image of that x-ray is burned into my memory: clusters of white spots spread out across both sides of...   Read More

What we’ve learned from three years of fighting COVID-19

By Andrew Powaleny  |    March 20, 2023
Three years ago, amidst an unprecedented public health crisis, biopharmaceutical industry made a commitment to fight COVID-19. Leveraging decades of research and investments in emerging technologies...   Read More

What you should know about RSV

By Michael Ybarra  |    November 15, 2022
You are probably reading a lot about a surge of cases of respiratory viruses like respiratory syncytial virus (RSV), influenza (the flu) and SARS-CoV-2, which causes COVID-19. The triple threat of...   Read More

Word of the Month: Long COVID

By Michael Ybarra  |    October 19, 2022
What is Long COVID?   Read More

Protecting against influenza: A conversation with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus

By Michael Ybarra  |    October 13, 2022
Our industry is at the forefront of fighting the annual influenza virus. I recently had the chance to connect with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus about...   Read More

Partnerships are driving global COVID-19 treatment access

By Megan Van Etten  |    September 22, 2022
Through the constant efforts of U.S. innovators and their global partners, COVID-19 treatments have continued to be distributed to patients around the world — changing the pandemic’s treatment...   Read More

ICYMI: PhRMA’s Ubl pens op-ed on IP waiver for COVID-19 technologies

By Megan Van Etten  |    July 15, 2022
Member states of the World Trade Organization (WTO) recently agreed to a waiver of intellectual property (IP) protections for COVID-19 vaccines as part of the Trade-Related Aspects of Intellectual...   Read More

New Data: COVID-19 vaccine global production capacity projected to exceed 20 billion doses this year

By Megan Van Etten  |    February 24, 2022
Biopharmaceutical companies are working across the industry and around the world to meet the global demand for COVID-19 vaccines. Companies have continued to ramp up their efforts to source needed...   Read More

What you need to know about newly authorized COVID-19 antiviral treatments

By Richard Moscicki, M.D.  |    February 22, 2022
In December 2021, the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) for the first two oral antivirals for the treatment of certain COVID-19 patients. These...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates